Roberto Cilia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3348544/publications.pdf

Version: 2024-02-01

106 papers	5,868 citations	61945 43 h-index	82499 72 g-index
107 all docs	107 docs citations	107 times ranked	7981 citing authors

#	Article	IF	Citations
1	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	9.4	502
2	Survival and dementia in <scp>GBA</scp>â€associated Parkinson's disease: <scp>T</scp>he mutation matters. Annals of Neurology, 2016, 80, 662-673.	2.8	312
3	Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. Movement Disorders, 2019, 34, 396-405.	2.2	252
4	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 2014, 137, 2731-2742.	3.7	251
5	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology, 2010, 75, 1711-1716.	1.5	191
6	Continuous theta burst stimulation of right dorsolateral prefrontal cortex induces changes in impulsivity level. Brain Stimulation, 2010, 3, 170-176.	0.7	150
7	Effects of <scp>COVID</scp>â€19 on Parkinson's Disease Clinical Features: A <scp>Communityâ€Based Caseâ€Control</scp> Study. Movement Disorders, 2020, 35, 1287-1292.	2.2	148
8	Impulsivity and compulsivity in drugâ€naÃ¯ve patients with Parkinson's disease. Movement Disorders, 2011, 26, 464-468.	2.2	139
9	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiology of Disease, 2010, 39, 98-104.	2.1	136
10	The relationship between impulsivity and impulse control disorders in Parkinson's disease. Movement Disorders, 2008, 23, 411-415.	2.2	131
11	Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 450-453.	0.9	130
12	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. Archives of Neurology, 2008, 65, 1604-11.	4.9	127
13	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. Movement Disorders, 2011, 26, 225-233.	2.2	109
14	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism and Related Disorders, 2006, 12, 410-419.	1.1	106
15	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: A [¹⁵O] H₂O PET study. Human Brain Mapping, 2009, 30, 3901-3909.	1.9	99
16	Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. Parkinsonism and Related Disorders, 2014, 20, 1382-1387.	1.1	93
17	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
18	Natural history of motor symptoms in Parkinsonâ€™s disease and the long-duration response to levodopa. Brain, 2020, 143, 2490-2501.	3.7	87

#	Article	IF	Citations
19	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS ONE, 2011, 6, e18301.	1.1	84
20	Mutant COQ2 in Multiple-System Atrophy. New England Journal of Medicine, 2014, 371, 80-83.	13.9	81
21	Behavioural Adverse Effects of Dopaminergic Treatments in ParkinsonÊ¼s Disease. Drug Safety, 2009, 32, 475-488.	1.4	80
22	Imaging essential tremor. Movement Disorders, 2010, 25, 679-686.	2.2	80
23	Mucuna pruriens in Parkinson disease. Neurology, 2017, 89, 432-438.	1.5	79
24	Surgical, Medical, and Hardware Adverse Events in a Series of 141 Patients Undergoing Subthalamic Deep Brain Stimulation for Parkinson Disease. World Neurosurgery, 2010, 73, 338-344.	0.7	77
25	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	2.2	73
26	Impulse control disorders in Parkinsonâ€™s disease: seeking a roadmap toward a better understanding. Brain Structure and Function, 2011, 216, 289-299.	1.2	72
27	The gut microbiome in Parkinson's disease: A culprit or a bystander?. Progress in Brain Research, 2020, 252, 357-450.	0.9	70
28	Striatal dopamine transporter abnormalities in patients with essential tremor. Nuclear Medicine Communications, 2008, 29, 349-353.	0.5	69
29	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. European Radiology, 2017, 27, 2665-2675.	2.3	66
30	Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 1215-1220.	1.1	63
31	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. Parkinsonism and Related Disorders, 2007, 13, 290-294.	1.1	61
32	Diagnostic agreement in patients with psychogenic movement disorders. Movement Disorders, 2012, 27, 548-552.	2.2	60
33	DNAJC12 and dopaâ€responsive nonprogressive parkinsonism. Annals of Neurology, 2017, 82, 640-646.	2.8	60
34	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. NeuroReport, 2007, 18, 1499-1502.	0.6	59
35	The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism and Related Disorders, 2012, 18, 775-780.	1.1	58
36	Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 311-318.	0.9	57

#	Article	IF	Citations
37	Parkinson's disease beyond 20â€...years. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 849-855.	0.9	55
38	Dementia in Parkinson's disease: Is male gender a risk factor?. Parkinsonism and Related Disorders, 2016, 26, 67-72.	1.1	52
39	Efficacy of rasagiline and selegiline in Parkinsonâ€™s disease: a head-to-head 3-year retrospective caseâ€“control study. Journal of Neurology, 2017, 264, 1254-1263.	1.8	52
40	Brain SPECT imaging in multiple system atrophy. Journal of Neural Transmission, 2005, 112, 1635-1645.	1.4	50
41	Skin Biopsy May Help to Distinguish Multiple System Atrophyâ€“Parkinsonism from Parkinson's Disease With Orthostatic Hypotension. Movement Disorders, 2020, 35, 1649-1657.	2.2	50
42	Cognitive status of patients with Parkinsonâ€™s disease and pathological gambling. Journal of Neurology, 2010, 257, 247-252.	1.8	49
43	Extradural motor cortex stimulation in Parkinson's disease. Movement Disorders, 2007, 22, 111-114.	2.2	46
44	Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. Journal of the Neurological Sciences, 2016, 365, 175-180.	0.3	44
45	Parkin analysis in early onset Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 326-333.	1.1	42
46	Striatal dopamine transporter binding in Parkinson's disease associated with theLRRK2 Gly2019Ser mutation. Movement Disorders, 2006, 21, 1144-1147.	2.2	41
47	Î±-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinsonâ€™s disease. Brain, 2020, 143, 920-931.	3.7	41
48	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. Clinical Neurology and Neurosurgery, 2009, 111, 140-146.	0.6	40
49	Psychiatric symptoms in Parkinsonâ€™s disease assessed with the SCL-90R self-reported questionnaire. Neurological Sciences, 2010, 31, 35-40.	0.9	40
50	LRRK2 mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population. Parkinsonism and Related Disorders, 2014, 20, 911-914.	1.1	40
51	Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism and Related Disorders, 2018, 49, 60-66.	1.1	39
52	The SPID-GBA study. Neurology: Genetics, 2020, 6, e523.	0.9	37
53	Anatomical identification of active contacts in subthalamic deep brain stimulation. World Neurosurgery, 2007, 67, 140-146.	1.3	35
54	Longâ€term cognitive followâ€up of Parkinson's disease patients with impulse control disorders. Movement Disorders, 2015, 30, 696-704.	2.2	35

#	Article	IF	Citations
55	Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism. Archives of Neurology, 2007, 64, 1002.	4.9	33
56	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. Parkinsonism and Related Disorders, 2013, 19, 557-559.	1.1	33
57	Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. Parkinsonism and Related Disorders, 2020, 75, 130-132.	1.1	30
58	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Movement Disorders, 2006, 21, 417-418.	2.2	28
59	No association of GBA mutations and multiple system atrophy. European Journal of Neurology, 2013, 20, e61-2.	1.7	28
60	Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient. Movement Disorders, 2019, 34, 757-759.	2.2	28
61	Screening for the Presence of FMR1 Premutation Alleles in Women With Parkinsonism. Archives of Neurology, 2009, 66, 244-9.	4.9	27
62	Does Gut Microbiota Influence the Course of Parkinsonâ€™s Disease? A 3-Year Prospective Exploratory Study in de novo Patients. Journal of Parkinson's Disease, 2021, 11, 159-170.	1.5	27
63	Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 96-103.	1.1	26
64	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. Journal of Neurology, 2020, 267, 2949-2960.	1.8	26
65	Screening LRRK2 gene mutations in patients with Parkinsonâ€™s disease in Ghana. Journal of Neurology, 2012, 259, 569-570.	1.8	24
66	Cardiometabolic factors and disease duration in patients with Parkinsonâ€™s disease. Nutrition, 2013, 29, 1331-1335.	1.1	24
67	Low Prevalence of NOTCH2NLC GGC Repeat Expansion in White Patients with Movement Disorders. Movement Disorders, 2021, 36, 251-255.	2.2	23
68	Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology, 2014, 83, 1155-1162.	1.5	22
69	Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status interaction. Parkinsonism and Related Disorders, 2013, 19, 72-76.	1.1	21
70	Nutritional characterisation of Zambian Moringa oleifera: acceptability and safety of short-term daily supplementation in a group of malnourished girls. International Journal of Food Sciences and Nutrition, 2019, 70, 107-115.	1.3	21
71	Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. European Journal of Neurology, 2008, 15, 22-28.	1.7	18
72	Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinsonâ€™s Disease and Atypical Parkinsonisms. Frontiers in Neuroscience, 2020, 14, 624.	1.4	17

#	Article	IF	Citations
73	Role of Lysosomal Gene Variants in Modulating <scp>GBA</scp>â€Associated Parkinson's Disease Risk. Movement Disorders, 2022, 37, 1202-1210.	2.2	17
74	Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsyâ€Parkinsonism</scp> From <scp>Parkinson's Disease</scp>. Movement Disorders, 2022, 37, 1272-1281.	2.2	17
75	Reversible dopamine transporter reduction in drugâ€induced parkinsonism. Movement Disorders, 2014, 29, 575-577.	2.2	16
76	Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 305-345.	0.9	16
77	Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?. Parkinsonism and Related Disorders, 2020, 73, 3-7.	1.1	16
78	The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Movement Disorders, 2012, 27, 800-801.	2.2	15
79	Short- and long-term motor outcome ofÂSTN-DBS in Parkinsonâ€™s Disease: focus on sex differences. Neurological Sciences, 2022, 43, 1769-1781.	0.9	15
80	Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. European Journal of Neurology, 2007, 14, 944-946.	1.7	14
81	A Novel Polymorphic APâ€1 Binding Element of the GFAP Promoter is Associated with Different Allelic Transcriptional Activities. Annals of Human Genetics, 2010, 74, 506-515.	0.3	14
82	Nutritional status and dietary habits in Parkinsonâ€™s disease patients in Ghana. Nutrition, 2013, 29, 470-473.	1.1	14
83	Inhibitory control dysfunction in parkinsonian impulse control disorders. Brain, 2020, 143, 3734-3747.	3.7	13
84	Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study. Journal of Molecular Neuroscience, 2013, 51, 380-388.	1.1	12
85	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. European Journal of Neurology, 2007, 14, 070206022829003-???.	1.7	11
86	Parkinsonâ€™s disease in sub-Saharan Africa: step-by-step into the challenge. Neurodegenerative Disease Management, 2011, 1, 193-202.	1.2	11
87	DJ1 analysis in a large cohort of Italian early onset Parkinson Disease patients. Neuroscience Letters, 2013, 557, 165-170.	1.0	11
88	LRRK2â€G2019S mutation is not associated with an increased cancer risk: A kinâ€cohort study. Movement Disorders, 2014, 29, 1325-1326.	2.2	11
89	Clinical correlates of serum 25-hydroxyvitamin D in Parkinsonâ€™s disease. Nutritional Neuroscience, 2022, 25, 1128-1136.	1.5	11
90	Impulse Control Disorders are Associated with Multiple Psychiatric Symptoms in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 507-515.	1.5	10

#	Article	IF	Citations
91	Sleep in Genetically Confirmed Pantothenate Kinase-Associated Neurodegeneration: A Video-Polysomnographic Study. Parkinson's Disease, 2010, 2010, 1-4.	0.6	9
92	Cortical visual evoked potentials recorded after optic tract near field stimulation during GPi-DBS in non-cooperative patients. Clinical Neurology and Neurosurgery, 2011, 113, 119-122.	0.6	9
93	Levodopaâ€“carbidopa intrajejunal infusion in Parkinsonâ€™s disease: untangling the role of age. Journal of Neurology, 2021, 268, 1728-1737.	1.8	9
94	Third cranial nerve palsy? Look for a sicca syndrome. Journal of the Neurological Sciences, 2007, 253, 88-89.	0.3	8
95	Multiple compulsive behaviors in multiple system atrophy: The importance of predisposition to addiction. Parkinsonism and Related Disorders, 2014, 20, 355-357.	1.1	8
96	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of Neural Transmission, 2015, 122, 799-808.	1.4	7
97	Saposin D variants are not a common cause of familial Parkinsonâ€™s disease among Italians. Brain, 2020, 143, e71-e71.	3.7	7
98	Parkinsonism and Nigrostriatal Damage Secondary to <scp>CSF1R</scp>â€Related Primary Microgliopathy. Movement Disorders, 2020, 35, 2360-2362.	2.2	6
99	Resting state oscillations suggest a motor component of Parkinsonâ€™s Impulse Control Disorders. Clinical Neurophysiology, 2019, 130, 2065-2075.	0.7	4
100	Meningioma with intense I¹²³ FPâ€CIT uptake. Movement Disorders, 2012, 27, 1744-1745.	2.2	3
101	How neurodegeneration, dopamine and maladaptive behavioral learning interact to produce impulse control disorders in Parkinsonâ€™s disease. Basal Ganglia, 2012, 2, 195-199.	0.3	3
102	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism and Related Disorders, 2014, 20, 1181-1185.	1.1	3
103	Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 323-324.	0.9	1
104	Effects of liraglutide in the treatment of severe obesity in a young patient with parkinsonâ€™s disease. Journal of the Neurological Sciences, 2019, 405, 309.	0.3	1
105	Uncovering Levodopaâ€Responsive Dystonic Tremor after Midbrain Stroke. Movement Disorders Clinical Practice, 2021, 8, 980-982.	0.8	1
106	Cerebrospinal fluid neuropathological biomarkers in beta-propeller protein-associated neurodegeneration, with complicated parkinsonian phenotype. Parkinsonism and Related Disorders, 2022, 98, 38-40.	1.1	0